Nadolol - Invion

Drug Profile

Nadolol - Invion

Alternative Names: INV 102; INV102 controlled release; INV102 CR

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inverseon
  • Developer Invion
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta adrenergic receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease

Highest Development Phases

  • Phase II Asthma; Smoking withdrawal
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 26 Sep 2017 Nadolol is still at phase II development stage for Asthma and Smoking withdrawal in USA (PO) (Invion Annual report, June 2017)
  • 30 Jun 2017 Nadolol from Invion is available for licensing as of 26 Sep 2017. http://inviongroup.com/investors/
  • 07 Jul 2016 Invion plans a phase III trial for Smoking withdrawal (in patients with Chronic obstructive pulmonary disease) in USA (PO) (Invion investor newsletter, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top